NewAmsterdam Pharma (NAMS) Other Non Operating Income (2023 - 2026)

NewAmsterdam Pharma has reported Other Non Operating Income for 4 years, with the latest figure at -$1.6 million in Q1 2026.

• Quarterly Other Non Operating Income fell 137.57% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 million (up 8241.59% YoY) and the FY2025 annual result came in at $15.3 million, up 332.37% from the prior year.
• Other Non Operating Income eased to -$1.6 million in Q1 2026 per NAMS's latest filing, from $2.2 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $8.6 million in Q2 2025 and troughed at -$7.9 million in Q4 2024.
• A 4-year average of $936846.2 and a median of $218000.0 in 2025 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2024 and 2025: Other Non Operating Income sank 1280.56% in 2024, then jumped 967.81% in 2025.
• Over 4 years, Other Non Operating Income stood at $5.2 million in 2023, then sank by 250.79% to -$7.9 million in 2024, then jumped by 127.9% to $2.2 million in 2025, then plunged by 173.49% to -$1.6 million in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered -$1.6 million, $2.2 million, and $218000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.